TRANSPERITONEAL SIGMOIDOTOMY FOR THE REMOVAL OF TUMORS IN THE MUCOUD MEMBRANE

W. Mayo

DOI: https://doi.org/10.1097/00000658-191707000-00008

IF: 13.787

1917-07-01

Annals of Surgery

Abstract:

What problem does this paper attempt to address?

Targeting PfCLK3 with Covalent Inhibitors: A Novel Strategy for Malaria Treatment

Andrew Jamieson,Skye Brettell,Omar Jahna,Abbey Begen,Gillian Cann,Niniola Olaniyan,Saumya Sharma,Tamas Yelland,Alison Hole,Benazir Alam,Ross Gillespie,Michael Capper,Graeme Milligan,David Clarke,Andrew Tobin

DOI: https://doi.org/10.26434/chemrxiv-2024-d62kp

2024-05-21

Abstract:Malaria continues to pose a significant global health threat, with the number of deaths exceeding 600,000 annually. Acquired resistance to frontline drugs by the most deadly parasite, Plasmodium falciparum, means this number is increasing each year. There is therefore an urgent unmet need for new medicines with novel mechanisms of action. In this work, we solved the co-crystal structure of the essential malarial kinase PfCLK3 with the reversible inhibitor TCMDC-135051 1. This facilitated the rational design of covalent inhibitors of this validated drug target. An allosteric cysteine residue (Cys368) that is poorly conserved in the human kinome was targeted to improve the selectivity of hit molecules. Structure-based drug design yielded chloroacetamide 4, which displays low nanomolar potency and covalent inhibition in both recombinant protein and P. falciparum killing assays. Efficacy in parasites was maintained when 4 was washed out 6 hours after exposure. Compound 4 showed significantly improved kinase selectivity relative to TCMDC-135051 1, and cell viability experiments in HepG2 cultures also demonstrated an over 500-fold selectivity index relative to P. falciparum parasites. To our knowledge, compound 4 represents the first covalent inhibitor of a malarial kinase. Its covalency, efficacy and selectivity for PfCLK3 makes it a promising lead in the search for a single-dose cure for malaria.

Chemistry
Structure-Based Virtual Screening, Insilico Docking, ADME Prediction, and Molecular Dynamics Studies for Identification of Potential NMT Inhibitors Against Malaria

Mohan Anbuselvam,C Ji Katherine,Anbuselvam Jeeva,Hai-Feng Ji

DOI: https://doi.org/10.21203/rs.3.rs-1199949/v1

2021-01-01

Abstract:Abstract One of the major public health problems globally, malaria, is mainly caused protozoan parasites from the genus Plasmodium, and commonly spreads to people through the bites of infected female mosquitoes of the genus Anopheles. Strategies for treatment, prevention, and control are available for malaria but the eradication of malaria still poses great challenge due to plasmodium’s drug resistance over the past decades. Development of novel antimalarial drugs remains a significant task to protect people from malaria. N-Myristoyl transferase is responsible for the N-Myristoylation catalysis process and the survival of Plasmodium species. Thus, it is considered a therapeutic drug target in protozoans and was recently validated as a significant target for Plasmodium vivax. In this present scenario, we endeavour to identify effective NMT inhibitors to prevent the onset of malaria in the human species. Initially, the structure-based virtual screening was executed against ZINC database and four potential candidates for NMT were identified. Furthermore, the four identified compounds were subjected to ADME prediction and all the four compounds found within adequate range with predicted ADME properties. Eventually, we conducted the molecular dynamics simulation to investigate the binding stability of top three protein-ligand complexes at different time scale by employing the tool Desmond. The molecular dynamics simulation studies revealed the protein-ligand complexes were stable throughout the entire simulation. Besides, we noticed that the residues ASN 365, PHE 103 and HIS 213 of NMT were crucially involved in the formation of various intermolecular interactions, significantly contributing to the stability of protein-ligand complexes. From this computational investigation, we suggest that the three identified potential compounds are extremely useful for further lead optimization and drug development.
Discovery of 3-Cinnamamido-n-substituted Benzamides As Potential Antimalarial Agents

Haicheng Liu,Yushi Futamura,Honghai Wu,Aki Ishiyama,Taotao Zhang,Tao Shi,Qunxiong Zheng,Masato Iwatsuki,Satoshi Omura,Hongbin Zou,Hiroyuki Osada

DOI: https://doi.org/10.2174/1573406416666200817160708

2021-01-01

Medicinal Chemistry

Abstract:Background: Malaria is one of the most devastating parasitic diseases, yet the discovery of antimalarial agents remains profoundly challenging. Very few new antimalarials have been developed in the past 50 years, while the emergence of drug-resistance continues to appear. Objective: This study focuses on the discovery, design, synthesis, and antimalarial evaluation of 3- cinnamamido-N-substituted benzamides. Methods: In this study, a screening of our compound library was carried out against the multidrugsensitive Plasmodium falciparum 3D7 strain. Derivatives of the hit were designed, synthesized and tested against P. falciparum 3D7 and the in vivo antimalarial activity of the most active compounds was evaluated using the method of Peters’ 4-day suppressive test. Results: The retrieved hit compound 1 containing a 3-cinnamamido-N-substituted benzamide skeleton showed moderate antimalarial activity (IC50 = 1.20 μM) for the first time. A series of derivatives were then synthesized through a simple four-step workflow, and half of them exhibited slightly better antimalarial effect than the precursor 1 during the subsequent in vitro assays. Additionally, compounds 11, 23, 30 and 31 displayed potent activity with IC50 values of approximately 0.1 μM, and weak cytotoxicity against mammalian cells. However, in vivo antimalarial activity is not effective, which might be ascribed to the poor solubility of these compounds. Conclusion: In this study, the phenotypic screen of our compound library resulted in the first report of a 3-cinnamamide framework with antimalarial activity and 40 derivatives were then designed and synthesized. Subsequent structure-activity studies showed that compounds 11, 23, 30 and 31 exhibited the most potent and selective activity against the P. falciparum 3D7 strain with IC50 values around 0.1 μM. Our work herein sets another example of phenotypic screen-based drug discovery, leading to potentially promising candidates of novel antimalarial agents once given further optimization.
Target Elucidation by Cocrystal Structures of Nadh-Ubiquinone Oxidoreductase of Plasmodium Falciparum (pfndh2) with Small Molecule to Eliminate Drug-Resistant Malaria

Yiqing Yang,You Yu,Xiaolu Li,Jing Li,Yue Wu,Jie Yu,Jingpeng Ge,Zhenghui Huang,Lubin Jiang,Yu Rao,Maojun Yang

DOI: https://doi.org/10.1021/acs.jmedchem.6b01733

IF: 8.039

2017-01-01

Journal of Medicinal Chemistry

Abstract:Drug-resistant malarial strains have been continuously emerging recently, which posts a great challenge for the global health. Therefore, new antimalarial drugs with novel targeting mechanisms are urgently needed for fighting drug-resistant malaria. NADH-ubiquinone oxidoreductase of Plasmodium falciparum (PfNDH2) represents a viable target for antimalarial drug development. However, the absence of structural information on PfNDH2 limited rational drug design and further development. Herein, we report high resolution crystal structures of the PfNDH2 protein for the first time in Apo-, NADH-, and RYL-552 (a new inhibitor) bound states. The PfNDH2 inhibitor exhibits excellent potency against both drug -resistant strains in vitro and parasite-infected mice in vivo via a potential allosteric mechanism. Furthermore, it was found that the inhibitor can be used in combination with dihydroartemisinin (DHA) synergistically. These findings not only are important for malarial PfNDH2 protein-based drug development but could also have broad implications for other NDH2-containing pathogenic microorganisms such as Mycobacterium tuberculosis.
Activity refinement of aryl amino acetamides that target the P. falciparum STAR-related lipid transfer 1 protein

William Nguyen,Coralie Boulet,Madeline G. Dans,Katie Loi,Kate E. Jarman,Gabrielle M. Watson,Wai-Hong Tham,Kate J. Fairhurst,Tomas Yeo,David A. Fidock,Sergio Wittlin,Mrittika Chowdury,Tania F. de Koning-Ward,Gong Chen,Dandan Yan,Susan A. Charman,Delphine Baud,Stephen Brand,Paul F. Jackson,Alan F. Cowman,Paul R. Gilson,Brad E. Sleebs

DOI: https://doi.org/10.1016/j.ejmech.2024.116354

IF: 7.088

2024-03-28

European Journal of Medicinal Chemistry

Abstract:Malaria is a devastating disease that causes significant morbidity worldwide. The development of new antimalarial chemotypes is urgently needed because of the emergence of resistance to frontline therapies. Independent phenotypic screening campaigns against the Plasmodium asexual parasite, including our own, identified the aryl amino acetamide hit scaffold. In a prior study, we identified the STAR-related lipid transfer protein (PfSTART1) as the molecular target of this antimalarial chemotype. In this study, we combined structural elements from the different aryl acetamide hit subtypes and explored the structure-activity relationship. It was shown that the inclusion of an endocyclic nitrogen, to generate the tool compound WJM-715, improved aqueous solubility and modestly improved metabolic stability in rat hepatocytes. Metabolic stability in human liver microsomes remains a challenge for future development of the aryl acetamide class, which was underscored by modest systemic exposure and a short half-life in mice. The optimized aryl acetamide analogs were cross resistant to parasites with mutations in PfSTART1, but not to other drug-resistant mutations, and showed potent binding to recombinant PfSTART1 by biophysical analysis, further supporting PfSTART1 as the likely molecular target. The optimized aryl acetamide analogue, WJM-715 will be a useful tool for further investigating the druggability of PfSTART1 across the lifecycle of the malaria parasite.

chemistry, medicinal
Structure of complex III with bound antimalarial agent CK-2-68 provides insights into selective inhibition of Plasmodium cytochrome bc1 complexes

Lothar Esser,Fei Zhou,Allison Zeher,Weimin Wu,Rick Huang,Chang-An Yu,Kristin D Lane,Thomas E Wellems,Di Xia

DOI: https://doi.org/10.1016/j.jbc.2023.104860

Abstract:Among the various components of the protozoan Plasmodium mitochondrial respiratory chain, only Complex III is a validated cellular target for antimalarial drugs. The compound CK-2-68 was developed to specifically target the alternate NADH dehydrogenase of the malaria parasite respiratory chain, but the true target for its antimalarial activity has been controversial. Here, we report the cryo-EM structure of mammalian mitochondrial Complex III bound with CK-2-68 and examine the structure-function relationships of the inhibitor's selective action on Plasmodium. We show that CK-2-68 binds specifically to the quinol oxidation site of Complex III, arresting the motion of the iron-sulfur protein subunit, which suggests an inhibition mechanism similar to that of Pf-type Complex III inhibitors such as atovaquone, stigmatellin, and UHDBT. Our results shed light on the mechanisms of observed resistance conferred by mutations, elucidate the molecular basis of the wide therapeutic window of CK-2-68 for selective action of Plasmodium vs. host cytochrome bc1, and provide guidance for future development of antimalarials targeting Complex III.
Development of novel anti-malarial from structurally diverse library of molecules, targeting plant-like CDPK1, a multistage growth regulator of P. falciparum

Ravi Jain,Sakshi Gupta,Manoj Munde,Soumya Pati,Shailja Singh

DOI: https://doi.org/10.1042/BCJ20200045

2020-05-29

Abstract:Upon Plasmodium falciparum merozoites exposure to low [K+] environment in blood plasma, there is escalation of cytosolic [Ca2+] which activates Ca2+-Dependent Protein Kinase 1 (CDPK1), a signaling hub of intra-erythrocytic proliferative stages of parasite. Given its high abundance and multidimensional attributes in parasite life-cycle, this is a lucrative target for designing antimalarials. Towards this, we have virtually screened MyriaScreenII diversity collection of 10,000 drug-like molecules, which resulted in 18 compounds complementing ATP-binding pocket of CDPK1. In vitro screening for toxicity in mammalian cells revealed that these compounds are non-toxic in nature. Furthermore, SPR analysis demonstrated differential binding affinity of these compounds towards recombinantly purified CDPK1 protein. Selection of lead compound 1 was performed by evaluating their inhibitory effects on phosphorylation and ATP binding activities of CDPK1. Furthermore, in vitro biophysical evaluations by ITC and FS revealed that binding of compound 1 is driven by formation of energetically favorable non-covalent interactions, with different binding constants in presence and absence of Ca2+, and TSA authenticated stability of compound 1 bound CDPK1 complex. Finally, compound 1 strongly inhibited intra-erythrocytic growth of P. falciparum in vitro. Conceivably, we propose a novel CDPK1-selective inhibitor, step towards developing pan-CDPK kinase inhibitors, prerequisite for cross-stage anti-malarial protection.
Development of novel anti-malarial from structurally diverse library of molecules, targeting plant-like Calcium Dependent Protein Kinase 1, a multistage growth regulator of P. falciparum

Ravi Jain,Sakshi Gupta,Manoj Munde,Soumya Pati,Shailja Singh

DOI: https://doi.org/10.1101/2020.01.14.907147

2020-01-15

Abstract:Abstract Upon Plasmodium falciparum merozoites exposure to low [K + ] environment in blood plasma, there is escalation of cytosolic [Ca 2+ ] which activates Ca 2+ -Dependent Protein Kinase 1 (CDPK1), a signaling hub of intra-erythrocytic proliferative stages of parasite. Given its high abundance and multidimensional attributes in parasite life-cycle, this is a lucrative target for desiging antimalarials. Towards this, we have virtually screened MyriaScreenII diversity collection of 10,000 drug-like molecules, which resulted in 18 compounds complementing ATP-binding pocket of CDPK1. In vitro screening for toxicity in mammalian cells revealed that these compounds are non-toxic in nature. Further, SPR analysis demonstrated differential binding affinity of these compounds towards recombinantly purified CDPK1 protein. Selection of lead compound 1 was performed by evaluating their inhibitory effects on phosphorylation and ATP binding activities of CDPK1. Further, in vitro biophysical evaluations by ITC and FS revealed that binding of compound 1 is driven by formation of energetically favorable non-covalent interactions, with different binding constants in presence and absence of Ca 2+ , and TSA authenticated stability of compound 1 bound CDPK1 complex. Finally, compound 1 strongly inhibited intra-erythrocytic growth of P. falciparum in vitro . Concievably, we propose a novel CDPK1-selective inhibitor, step towards developing pan-CDPK kinase inhibitors, prerequisite for cross-stage anti-malarial protection.
Endothelial immunogenicity – A matter of matrix microarchitecture

H. Methe,Shmuel Hess,E. Edelman

DOI: https://doi.org/10.1160/TH07-01-0043

2007-07-06

Thrombosis and Haemostasis

Abstract:Summary The endothelium is a highly specialized active interface between blood and the underlying tissues, maintaining vascular tone, thrombo-resistance and selective permeability to cells and proteins. It is also an important regulator of inflammatory diseases, and endothelial-leukocyte interactions often herald complex diseases with an inflammatory component.Yet, the exact mechanisms promoting immune activation of endothelial cells (EC) are incompletely understood. Knowledge is accumulating that the immediate environment defines the cellular phenotype, whereby matrix composition and spatial formation (three- versus two-dimensional) seem to act as pivotal mediators. Here we summarize current findings denoting a key role of matrix environment in regulating endothelial immunogenicity. The immune response to three-dimensional matrix-embedded EC stands in stark contrast to the response engendered by injection of these same cells in their free state. Matrix-embedding confers a quiescent endothelial state with reduced expression levels of chemokines, adhesion, costimulatory, and major histocompatibility complex II molecules. Compared to EC grown on two-dimensional tissue culture plates, cytokine-stimulation of matrixembedded EC results in significantly reduced adhesion of natural killer cells and proliferation of co-cultivated allogeneicT cells. On the contrary, matrix-embedded EC induce an immune-inhibitory phenotype of dendritic cells and T regulatory cells to a greater extent than non-embedded EC. As vascular diseases are associated with profound changes in basement membrane composition and overall tissue architecture, our results indicate that the immediate environment of EC might play a pivotal role in initiating and regulating of different vascular diseases. Cell-matrix interconnections appear to govern endothelial immunogenicity and interactions between EC and immune cells.
On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity

Rebecca C. S. Edgar,Tess R. Malcolm,Ghizal Siddiqui,Carlo Giannangelo,Natalie A. Counihan,Matthew Challis,Sandra Duffy,Mrittika Chowdhury,Jutta Marfurt,Madeline Dans,Grennady Wirjanata,Rintis Noviyanti,Kajal Daware,Chathura D. Suraweera,Ric N. Price,Sergio Wittlin,Vicky M. Avery,Nyssa Drinkwater,Susan A. Charman,Darren J. Creek,Tania F. de Koning-Ward,Peter J. Scammells,Sheena McGowan

DOI: https://doi.org/10.1128/mbio.00966-24

IF: 6.4

2024-05-10

mBio

Abstract:ABSTRACT To combat the global burden of malaria, development of new drugs to replace or complement current therapies is urgently required. Here, we show that the compound MMV1557817 is a selective, nanomolar inhibitor of both Plasmodium falciparum and Plasmodium vivax aminopeptidases M1 and M17, leading to inhibition of end-stage hemoglobin digestion in asexual parasites. MMV1557817 can kill sexual-stage P. falciparum , is active against murine malaria, and does not show any shift in activity against a panel of parasites resistant to other antimalarials. MMV1557817 -resistant P. falciparum exhibited a slow growth rate that was quickly outcompeted by wild-type parasites and were sensitized to the current clinical drug, artemisinin. Overall, these results confirm MMV1557817 as a lead compound for further drug development and highlights the potential of dual inhibition of M1 and M17 as an effective multi-species drug-targeting strategy. IMPORTANCE Each year, malaria infects approximately 240 million people and causes over 600,000 deaths, mostly in children under 5 years of age. For the past decade, artemisinin-based combination therapies have been recommended by the World Health Organization as the standard malaria treatment worldwide. Their widespread use has led to the development of artemisinin resistance in the form of delayed parasite clearance, alongside the rise of partner drug resistance. There is an urgent need to develop and deploy new antimalarial agents with novel targets and mechanisms of action. Here, we report a new and potent antimalarial compound, known as MMV1557817 , and show that it targets multiple stages of the malaria parasite lifecycle, is active in a preliminary mouse malaria model, and has a novel mechanism of action. Excitingly, resistance to MMV15578117 appears to be self-limiting, suggesting that development of the compound may provide a new class of antimalarial.

microbiology
Structural Exploration of the PfBLM Helicase-ATP Binding Domain and Its Implications in the Quest for Antimalarial Therapies

Hattan S Gattan,Bassam M Al-ahmadi,Abdullah F Shater,Nizar H Saeedi,Mohammed H Alruhaili

DOI: https://doi.org/10.4103/jvbd.jvbd_176_23

2024-01-29

Journal of Vector Borne Diseases

Abstract:ABSTRACT Background & objectives: The battle against malaria has witnessed remarkable progress in recent years, characterized by increased funding, the development of life-saving tools, and a significant reduction in disease prevalence. Yet, the formidable challenge of drug resistance persists, threatening to undo these gains. Methods: To tackle this issue, it is imperative to identify new effective drug candidates against the malaria parasite and exhibit minimal toxicity. This study focuses on discovering such candidates by targeting PfRecQ1, also known as PfBLM, a vital protein within the malaria parasite. PfRecQ1 plays a crucial role in the parasite’s life cycle and DNA repair processes, making it an attractive drug development target. The research employs advanced computational techniques, including molecular modeling, structure-based virtual screening (SBVS), ADMET profiling, molecular docking, and dynamic simulations. Results: The study sources ligand molecules from the extensive MCULE database and utilizes strict filters to ensure the compounds meet essential criteria. Through these techniques, the research identifies MCULE-3763806507-0-9 as a promising anti-malarial drug candidate, surpassing the binding affinity of potential antimalarial drugs. However, it is essential to underscore that the drug-like properties are primarily based on in silico experiments, and wet lab experiments are necessary to validate these candidates’ therapeutic potential. Interpretation & conclusion: This study represents a critical step in addressing the challenge of drug resistance in the fight against malaria.

infectious diseases,tropical medicine,parasitology
Design, synthesis, and biological evaluation of multiple targeting antimalarials

Yiqing Yang,Tongke Tang,Xiaolu Li,Thomas Michel,Liqin Ling,Zhenghui Huang,Maruthi Mulaka,Yue Wu,Hongying Gao,Liguo Wang,Jing Zhou,Brigitte Meunier,Hangjun Ke,Lubin Jiang,Yu Rao

DOI: https://doi.org/10.1016/j.apsb.2021.05.008

IF: 14.903

2021-09-01

Acta Pharmaceutica Sinica B

Abstract:Malaria still threatens global health seriously today. While the current discoveries of antimalarials are almost totally focused on single mode-of-action inhibitors, multi-targeting inhibitors are highly desired to overcome the increasingly serious drug resistance. Here, we performed a structure-based drug design on mitochondrial respiratory chain of Plasmodium falciparum and identified an extremely potent molecule, RYL-581, which binds to multiple protein binding sites of P. falciparum simultaneously (allosteric site of type II NADH dehydrogenase, Qo and Qi sites of cytochrome bc 1). Antimalarials with such multiple targeting mechanism of action have never been reported before. RYL-581 kills various drug-resistant strains in vitro and shows good solubility as well as in vivo activity. This structure-based strategy for designing RYL-581 from starting compound may be helpful for other medicinal chemistry projects in the future, especially for drug discovery on membrane-associated targets.

pharmacology & pharmacy
[Susceptibility of the dromedary (Camelus dromedarius) to rotavirus infection].

L. Mahin,A. Schwers,M. Chadli,M. Maenhoudt,P. Pastoret

Abstract:
Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1

Madeline G Dans,Coralie Boulet,Gabrielle M Watson,William Nguyen,Jerzy M Dziekan,Cindy Evelyn,Kitsanapong Reaksudsan,Somya Mehra,Zahra Razook,Niall D Geoghegan,Michael J Mlodzianoski,Christopher Dean Goodman,Dawson B Ling,Thorey K Jonsdottir,Joshua Tong,Mufuliat Toyin Famodimu,Mojca Kristan,Harry Pollard,Lindsay B Stewart,Luke Brandner-Garrod,Colin J Sutherland,Michael J Delves,Geoffrey I McFadden,Alyssa E Barry,Brendan S Crabb,Tania F de Koning-Ward,Kelly L Rogers,Alan F Cowman,Wai-Hong Tham,Brad E Sleebs,Paul R Gilson

DOI: https://doi.org/10.1038/s41467-024-49491-8

2024-06-18

Abstract:With resistance to most antimalarials increasing, it is imperative that new drugs are developed. We previously identified an aryl acetamide compound, MMV006833 (M-833), that inhibited the ring-stage development of newly invaded merozoites. Here, we select parasites resistant to M-833 and identify mutations in the START lipid transfer protein (PF3D7_0104200, PfSTART1). Introducing PfSTART1 mutations into wildtype parasites reproduces resistance to M-833 as well as to more potent analogues. PfSTART1 binding to the analogues is validated using organic solvent-based Proteome Integral Solubility Alteration (Solvent PISA) assays. Imaging of invading merozoites shows the inhibitors prevent the development of ring-stage parasites potentially by inhibiting the expansion of the encasing parasitophorous vacuole membrane. The PfSTART1-targeting compounds also block transmission to mosquitoes and with multiple stages of the parasite's lifecycle being affected, PfSTART1 represents a drug target with a new mechanism of action.
The complex of Plasmodium falciparum falcipain-2 protease with an (E)-chalcone-based inhibitor highlights a novel, small, molecule-binding site

Jonathan M. Machin,Anastassia L. Kantsadi,Ioannis Vakonakis

DOI: https://doi.org/10.1186/s12936-019-3043-0

2019-12-01

Malaria Journal

Abstract:Abstract Background Malaria kills over 400,000 people each year and nearly half the world’s population live in at-risk areas. Progress against malaria has recently stalled, highlighting the need for developing novel therapeutics. The parasite haemoglobin degradation pathway, active in the blood stage of the disease where malaria symptoms and lethality manifest, is a well-established drug target. A key enzyme in this pathway is the papain-type protease falcipain-2. Methods The crystallographic structure of falcipain-2 at 3.45 Å resolution was resolved in complex with an (E)-chalcone small-molecule inhibitor. The falcipain-2–(E)-chalcone complex was analysed with reference to previous falcipain complexes and their similarity to human cathepsin proteases. Results The (E)-chalcone inhibitor binds falcipain-2 to the rear of the substrate-binding cleft. This is the first structure of a falcipain protease where the rear of the substrate cleft is bound by a small molecule. In this manner, the (E)-chalcone inhibitor mimics interactions observed in protein-based falcipain inhibitors, which can achieve high interaction specificity. Conclusions This work informs the search for novel anti-malaria therapeutics that target falcipain-2 by showing the binding site and interactions of the medically privileged (E)-chalcone molecule. Furthermore, this study highlights the possibility of chemically combining the (E)-chalcone molecule with an existing active-site inhibitor of falcipain, which may yield a potent and selective compound for blocking haemoglobin degradation by the malaria parasite.

infectious diseases,tropical medicine,parasitology
Development of peptidomimetic hydroxamates as PfA-M1 and PfA-M17 dual inhibitors: Biological evaluation and structural characterization by cocrystallization

Anil Kumar Marapaka,Priyanka Sankoju,Guozhen Zhang,Yongzheng Ding,Chunhua Ma,Vijaykumar Pillalamarri,Renu Sudhakar,Bharati Reddi,Puran Singh Sijwali,Yingjie Zhang,Anthony Addlagatta

DOI: https://doi.org/10.1016/j.cclet.2021.09.102

IF: 9.1

2022-05-01

Chinese Chemical Letters

Abstract:Plasmodium parasites causing malaria have developed resistance to most of the antimalarials in use, including the artemisinin-based combinations, which are the last line of defense against malaria. This necessitates the discovery of new targets and the development of novel antimalarials. Plasmodium falciparum alanyl aminopeptidase (PfA-M1) and leucyl aminopeptidase (PfA-M17) belong to the M1 and M17 family of metalloproteases respectively and play critical roles in the asexual erythrocytic stage of development. These enzymes have been suggested as potential antimalarial drug targets. Herein we describe the development of peptidomimetic hydroxamates as PfA-M1 and PfA-M17 dual inhibitors. Most of the compounds described in this study display inhibition at sub-micromolar range against the recombinant PfA-M1 and PfA-M17. More importantly, compound 26 not only exhibits potent malarial aminopeptidases inhibitory activities (PfA-M1 Ki = 0.11 ± 0.0002 μmol/L, PfA-M17 Ki = 0.05 ± 0.005 μmol/L), but also possesses remarkable selectivity over the mammalian counterpart (pAPN Ki = 17.24 ± 0.08 μmol/L), which endows 26 with strong inhibition of the malarial parasite growth and negligible cytotoxicity on human cell lines. Crystal structures of PfA-M1 at atomic resolution in complex with four different compounds including compound 26 establish the structural basis for their inhibitory activities. Notably, the terminal ureidobenzyl group of 26 explores the S2' region where differences between the malarial and mammalian enzymes are apparent, which rationalizes the selectivity of 26. Together, our data provide important insights for the rational and structure-based design of selective and dual inhibitors of malarial aminopeptidases that will likely lead to novel chemotherapeutics for the treatment of malaria.

chemistry, multidisciplinary
Identification of novel Plasmodium falciparum dihydroorotate dehydrogenase inhibitors for malaria using in silico studies

Abdulrahim A. Alzain,Zain Alsharf M. Ahmed,Mariam A. Mahadi,Elaf A khairy,Fatima A. Elbadwi

DOI: https://doi.org/10.1016/j.sciaf.2022.e01214

2022-07-01

Scientific African

Abstract:Malaria, that ancient infectious disease is considered a great health problem due to its highly infectious and mortality rates. The more harmful kind of malaria is Plasmodium falciparum (Pf), accounting for over 1M fatalities yearly; unfortunately, existing medication regimens are hampered by resistance, necessitating the identification of novel targets against plasmodium species. Since the malaria parasite cannot recover pyrimidines, it must rely on de novo production to survive. Dihydroorotate dehydrogenase (DHODH), which facilitates the rate-limiting phase of that process, is therefore an interesting antimalarial target. In this context, computational screening comprising pharmacophore mapping, molecular docking, MM-GBSA calculations, ADME filtering and molecular dynamics were performed in order to identify novel and powerful PfDHODH inhibitors. A pharmacophore hypothesis with seven features was created and tested on 2 million compounds from the enamine database. Docking, MM-GBSA calculations, and ADME revealed ten hits with strong binding affinities and potential, stable binding energy, and drug-like properties. The top three hits were confirmed further using molecular dynamics simulations, which revealed that three of them were stable for the whole 100 ns simulation time. Relying on these findings, we recommend that Z1481646084, Z24317941, and Z951873618 be submitted for experimental verification as promising antimalarial gents.
Identification of Potent and Reversible Piperidine Carboxamides That Are Species-Selective Orally Active Proteasome Inhibitors to Treat Malaria

Aloysus Lawong,Suraksha Gahalawat,Sneha Ray,Nhi Ho,Yan Han,Kurt E. Ward,Xiaoyi Deng,Zhe Chen,Ashwani Kumar,Chao Xing,Varun Hosangadi,Kate J. Fairhurst,Kyuto Tashiro,Glen Liszczak,David M. Shackleford,Kasiram Katneni,Gong Chen,Jessica Saunders,Elly Crighton,Arturo Casas,Joshua J. Robinson,Leah S. Imlay,Xiaoyu Zhang,Andrew Lemoff,Zhiyu Zhao,Inigo Angulo-Barturen,Maria Belen Jimenez-Diaz,Sergio Wittlin,Simon F. Campbell,David A. Fidock,Benoit Laleu,Susan A. Charman,Joseph M. Ready,Margaret A. Phillips

DOI: https://doi.org/10.1016/j.chembiol.2024.07.001

IF: 9.039

2024-01-01

Cell Chemical Biology

Abstract:Malaria remains a global health concern as drug resistance threatens treatment programs. We identified a piperidine carboxamide (SW042) with anti-malarial activity by phenotypic screening. Selection of SW042-resistant Plasmodium falciparum (Pf) parasites revealed point mutations in the Pf_proteasome β5 active-site (Pfβ5). A potent analog (SW584) showed efficacy in a mouse model of human malaria after oral dosing. SW584 had a low propensity to generate resistance (minimum inoculum for resistance [MIR] >109) and was synergistic with dihydroartemisinin. Pf_proteasome purification was facilitated by His8-tag introduction onto β7. Inhibition of Pfβ5 correlated with parasite killing, without inhibiting human proteasome isoforms or showing cytotoxicity. The Pf_proteasome_SW584 cryoelectron microscopy (cryo-EM) structure showed that SW584 bound non-covalently distal from the catalytic threonine, in an unexplored pocket at the β5/β6/β3 subunit interface that has species differences between Pf and human proteasomes. Identification of a reversible, species selective, orally active series with low resistance propensity provides a path for drugging this essential target.
Discovery of dual-target natural antimalarial agents against DHODH and PMT of Plasmodium falciparum: pharmacophore modelling, molecular docking, quantum mechanics, and molecular dynamics simulations

E.M. Elamin,S.E. Eshage,S.M. Mohmmode,R.M. Mukhtar,M. Mahjoub,E. Sadelin,T.H. Shoaib,A. Edris,E.M. Elshamly,A.A. Makki,A. Ashour,A.E. Sherif,W. Osman,S.R.M. Ibrahim,G.A. Mohamed,A.A. Alzain

DOI: https://doi.org/10.1080/1062936X.2023.2251876

IF: 3.681

2023-09-05

SAR and QSAR in Environmental Research

Abstract:Malaria is a lethal disease that claims thousands of lives worldwide annually. The objective of this study was to identify new natural compounds that can target two P. falciparum enzymes; P. falciparu m Dihydroorotate dehydrogenase ( Pf DHODH) and P. falciparum phosphoethanolamine methyltransferase ( Pf PMT). To accomplish this, e-pharmacophore modelling and molecular docking were employed against Pf DHODH. Following this, 1201 natural compounds with docking scores of ≤ −7 kcal/mol were docked into the active site of the second enzyme PMT. The top nine compounds were subjected to further investigation using MM-GBSA free binding energy calculations and ADME analysis. The results revealed favourable free binding energy values better than the references, as well as acceptable pharmacokinetic properties. Compounds ZINC000013377887, ZINC000015113777, and ZINC000085595753 were scrutinized to assess their interaction stability with the Pf DHODH enzyme, and chemical stability reactivity using molecular dynamics (MD) simulation and density functional theory (DFT) calculations. These findings indicate that the three natural compounds are potential candidates for dual Pf DHODH and Pf PMT inhibitors for malaria treatment.

environmental sciences,toxicology,computer science, interdisciplinary applications,chemistry, multidisciplinary,mathematical & computational biology
Identification of mCMQ069, a novel antimalarial with potential for a single-dose cure and/or 28-day chemoprevention

Anil K Gupta,James Pedroarena,Armen Nazarian,Jenya Antonova-Koch,Frank Weiss,Krittikorn Kumpornsin,Victor Chi,Ashley K. Woods,Kyoung-Jin Lee,Sean B. Joseph,Shuangwei Li,Jason Brittain,Eugenio De Hostos,James Duffy,Anne Cooper,Peter G. Schultz,Case W. McNamara,Arnab K. Chatterjee

DOI: https://doi.org/10.1101/2024.07.01.601566

2024-07-01

Abstract:In efforts towards eliminating malaria, a discovery program was initiated to identify a novel antimalarial using KAF156 as a starting point. Following the most recent TCP/TPP guidelines, we have identified mCMQ069 with a predicted single oral dose for treatment (~40-106 mg) and one-month chemoprevention (~96-216 mg). We have improved unbound MPC and predicted human clearance by 18-fold and 10-fold respectively when compared to KAF156.

Microbiology

TRANSPERITONEAL SIGMOIDOTOMY FOR THE REMOVAL OF TUMORS IN THE MUCOUD MEMBRANE

Targeting PfCLK3 with Covalent Inhibitors: A Novel Strategy for Malaria Treatment

Structure-Based Virtual Screening, Insilico Docking, ADME Prediction, and Molecular Dynamics Studies for Identification of Potential NMT Inhibitors Against Malaria

Discovery of 3-Cinnamamido-n-substituted Benzamides As Potential Antimalarial Agents

Target Elucidation by Cocrystal Structures of Nadh-Ubiquinone Oxidoreductase of Plasmodium Falciparum (pfndh2) with Small Molecule to Eliminate Drug-Resistant Malaria

Activity refinement of aryl amino acetamides that target the P. falciparum STAR-related lipid transfer 1 protein

Structure of complex III with bound antimalarial agent CK-2-68 provides insights into selective inhibition of Plasmodium cytochrome bc1 complexes

Development of novel anti-malarial from structurally diverse library of molecules, targeting plant-like CDPK1, a multistage growth regulator of P. falciparum

Development of novel anti-malarial from structurally diverse library of molecules, targeting plant-like Calcium Dependent Protein Kinase 1, a multistage growth regulator of P. falciparum

Endothelial immunogenicity – A matter of matrix microarchitecture

On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity

Structural Exploration of the PfBLM Helicase-ATP Binding Domain and Its Implications in the Quest for Antimalarial Therapies

Design, synthesis, and biological evaluation of multiple targeting antimalarials

[Susceptibility of the dromedary (Camelus dromedarius) to rotavirus infection].

Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1

The complex of Plasmodium falciparum falcipain-2 protease with an (E)-chalcone-based inhibitor highlights a novel, small, molecule-binding site

Development of peptidomimetic hydroxamates as PfA-M1 and PfA-M17 dual inhibitors: Biological evaluation and structural characterization by cocrystallization

Identification of novel Plasmodium falciparum dihydroorotate dehydrogenase inhibitors for malaria using in silico studies

Identification of Potent and Reversible Piperidine Carboxamides That Are Species-Selective Orally Active Proteasome Inhibitors to Treat Malaria

Discovery of dual-target natural antimalarial agents against DHODH and PMT of Plasmodium falciparum: pharmacophore modelling, molecular docking, quantum mechanics, and molecular dynamics simulations

Identification of mCMQ069, a novel antimalarial with potential for a single-dose cure and/or 28-day chemoprevention